At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 420 enrolled
Drug / intervention
GSK Biologicals' quadrivalent influenza vaccine +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Immunogenicity and Safety Study of a GSK Influenza Vaccine Candidate GSK 2115160A in Adults.
In Brief
A Phase 1 clinical trial evaluating GSK Biologicals' quadrivalent influenza vaccine and GSK Biologicals' trivalent influenza vaccine for Influenza. Completed, enrolled 420 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the safety and immunogenicity of GSK influenza vaccine candidate compared to a licensed trivalent influenza vaccine in adults.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesCzechia
Collaborators--
Timeline
Phase 1CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 2008
Enrollment StartJul 2008
Primary CompletionJan 2009
TodayJul 2026
First PostedJul 14, 2008
Enrollment StartJul 14, 2008
Primary CompletionJan 28, 2009
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 18.0 years ago
Interventions
GSK Biologicals' quadrivalent influenza vaccinebiological
Single intramuscular dose on Day 0.
GSK Biologicals' trivalent influenza vaccinebiological
Single intramuscular dose on Day 0.